The United Kingdom and the United States have hammered out a important commercial pact that will maintain no levies on UK medicine shipments going into the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise expenditure on pharmaceuticals through the public health system. This commitment ensures that import taxes on these key products will stay at nothing for a duration of 36 months.
This agreement is in response to earlier threats to dramatically increase duties on branded drug products, with increases mentioned up to double the cost.
"This deal between the Britain reinforces the global environment for cutting-edge drugs and introduces long-overdue fairness to American-British pharmaceutical trade," a statement noted.
Trade Importance
Medicines are one of the Britain's largest exports to the America, which is easily the primary market for large British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of the third quarter, the UK shipped medicines valued at over eleven billion pounds to the US. This figure accounted for nearly one-fifth of total UK exports in that period.
"This deal protects employment, stimulates capital expenditure and paves the way for the UK to become a global hub for medical research," a minister commented.
Detailed NHS Changes
The deal entails several key changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to increase overall NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, refunds were more than 20%.
Recent Tensions
The pact follows a protracted row between the drug companies and the ministers over drug pricing and regulatory access.
These tensions were exacerbated by claims that US consumers were charged several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been directed toward American operations.
One official publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had declined as a share of its resources over the past decade.
